BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18381438)

  • 1. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
    Ambrosini G; Seelman SL; Qin LX; Schwartz GK
    Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
    Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
    Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
    Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
    Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
    Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
    Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
    Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
    Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
    Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
    Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
    Incles CM; Schultes CM; Kelland LR; Neidle S
    Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor.
    Demidenko ZN; Blagosklonny MV
    Cancer Res; 2004 May; 64(10):3653-60. PubMed ID: 15150125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
    Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
    Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
    Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
    Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
    FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
    McDermott U; Longley DB; Galligan L; Allen W; Wilson T; Johnston PG
    Cancer Res; 2005 Oct; 65(19):8951-60. PubMed ID: 16204068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.